Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases.
Administration, Intranasal
Administration, Oral
Animals
Animals, Genetically Modified
Biological Availability
Blood-Brain Barrier
/ metabolism
Brain
/ drug effects
Disease Models, Animal
Drug Carriers
/ chemistry
Drug Evaluation, Preclinical
Genetic Loci
/ genetics
Humans
Huntington Disease
/ drug therapy
Injections, Intraperitoneal
Injections, Intravenous
Injections, Intraventricular
Injections, Spinal
Nanoparticles
/ chemistry
Neuroprotective Agents
/ administration & dosage
Oligonucleotides, Antisense
/ administration & dosage
Peptides
/ antagonists & inhibitors
Permeability
Spinal Cord
/ drug effects
Spinocerebellar Ataxias
/ drug therapy
Tissue Distribution
Trinucleotide Repeat Expansion
Huntington’s disease
brain delivery
nanomedicine
nanoparticles
neurodegenerative diseases
polyglutamine
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
26
6
2020
medline:
12
10
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
Polyglutamine (polyQ) diseases, such as Huntington's disease and several types of spinocerebellar ataxias, are dominantly inherited progressive neurodegenerative disorders and characterized by the presence of expanded
Identifiants
pubmed: 32584043
doi: 10.1021/acs.molpharmaceut.0c00506
doi:
Substances chimiques
Drug Carriers
0
Neuroprotective Agents
0
Oligonucleotides, Antisense
0
Peptides
0
polyglutamine
26700-71-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM